阿米卡星不同给药方式治疗支气管扩张伴铜绿假单胞菌感染患者的效果观察
|
摘要
目的观察阿米卡星不同给药方式治疗支气管扩张伴铜绿假单胞菌感染患者的效果。方法 92例支气管扩张伴铜绿假单胞菌感染患者分别采用阿米卡星雾化吸入或静脉滴注治疗8 d,比较两组疗效、不良反应、实验室指标、莱塞斯特咳嗽生命质量问卷(LCQ)评分。结果两组疗效及不良反应差异无统计学意义(P>0.05);雾化吸入组治疗后白细胞、血降钙素原、C反应蛋白水平明显低于静脉滴注组,LCQ评分明显增高(P<0.01)。结论阿米卡星雾化吸入治疗支气管扩张伴铜绿假单胞菌感染患者可有效缓解症状,改善实验室指标。
Objective To observe clinical efficacy of different amikacin administration routes in bronchiectasis with Pseudomonas aeruginosa(PA) infection. Methods Ninety-two bronchiectasis patients with PA infection were treated with aerosol inhalation or intravenous infusion of amikacin for 8 days. Clinical efficacy, adverse reactions, laboratory parameters,and Leicester cough questionnaire(LCQ) were compared between 2 groups. Results Clinical efficacy and adverse reactions showed no significant difference between 2 groups(P>0.05). Post-therapeutic levels of leukocyte, procalcitonin and Creactive protein were lower, while LCQ scores were higher in aerosol inhalation group compared with intravenous infusion group(P<0.01). Conclusion Aerosol inhalation of amikacin can alleviate symptoms and improve laboratory indicators in bronchiectasis patients with PA infection.
Objective To observe clinical efficacy of different amikacin administration routes in bronchiectasis with Pseudomonas aeruginosa(PA) infection. Methods Ninety-two bronchiectasis patients with PA infection were treated with aerosol inhalation or intravenous infusion of amikacin for 8 days. Clinical efficacy, adverse reactions, laboratory parameters,and Leicester cough questionnaire(LCQ) were compared between 2 groups. Results Clinical efficacy and adverse reactions showed no significant difference between 2 groups(P>0.05). Post-therapeutic levels of leukocyte, procalcitonin and Creactive protein were lower, while LCQ scores were higher in aerosol inhalation group compared with intravenous infusion group(P<0.01). Conclusion Aerosol inhalation of amikacin can alleviate symptoms and improve laboratory indicators in bronchiectasis patients with PA infection.
引文
[1] SMITH M P.Diagnosis and management of bronchiectasis[J]. CMAJ, 2017, 189(24):E828-E835.
[2] DING C, YANG Z, WANG J, et al.Prevalence of Pseudomonas aeruginosa and antimicrobial-resistant Pseudomonas aeruginosa in patients with pneumonia in mainland China:a systematic review and meta-analysis[J]. Int J Infect Dis,2016, 49(C):119-128.
[3] GAO Y H, GUAN W J, ZHU Y N, et al. Antibiotic-resistant Pseudomonas aeruginosa infection in patients with bronchiectasis:prevalence, risk factors and prognostic implications[J]. Int J Chron Obstruct Pulmon Dis, 2018,13:237-246.
[4] BRIGNALL K, JAYARAMAN B, BIRRING S S. Quality of life and psychosocial aspects of cough[J]. Lung, 2008, 186(1 Supplement):55-58.
[5]成人支气管扩张症诊治专家共识编写组.成人支气管扩张症诊治专家共识[J].中华结核和呼吸杂志, 2012, 35(7):85-492.
[6] FUJITANI S, SUN Y, QUINTILIANI R D, et al. Pneumonia due to Pseudomonas aeruginosa:part II:antimicrobial resis-tance, pharmacodynamic concepts, and antibiotic therapy[J]. Chest, 2011, 139(5):1172-1185.
[7] GELLATLY S L, HANCOCK R E W. Pseudomonas aeruginosa:new insights into pathogenesis and host defenses[J]. Pathog Dis, 2013, 67(3):159-173.
[8]袁婧婧,关伟杰,李惠敏,等.吸入性抗生素治疗成人支气管扩张症的有效性与安全性[J].中华结核和呼吸杂志,2017, 40(1):61-63.
[9]李虎.雾化吸入阿米卡星药代动力学及对G-杆菌所致呼吸机相关性肺炎的治疗作用[D].复旦大学, 2012.
[10] XU L, ZHANG F, DU S, et al. Inhaled antibiotics in noncystic fibrosis bronchiectasis:A meta-analysis[J]. Pharmazie, 2016, 71(9):491-498.
[2] DING C, YANG Z, WANG J, et al.Prevalence of Pseudomonas aeruginosa and antimicrobial-resistant Pseudomonas aeruginosa in patients with pneumonia in mainland China:a systematic review and meta-analysis[J]. Int J Infect Dis,2016, 49(C):119-128.
[3] GAO Y H, GUAN W J, ZHU Y N, et al. Antibiotic-resistant Pseudomonas aeruginosa infection in patients with bronchiectasis:prevalence, risk factors and prognostic implications[J]. Int J Chron Obstruct Pulmon Dis, 2018,13:237-246.
[4] BRIGNALL K, JAYARAMAN B, BIRRING S S. Quality of life and psychosocial aspects of cough[J]. Lung, 2008, 186(1 Supplement):55-58.
[5]成人支气管扩张症诊治专家共识编写组.成人支气管扩张症诊治专家共识[J].中华结核和呼吸杂志, 2012, 35(7):85-492.
[6] FUJITANI S, SUN Y, QUINTILIANI R D, et al. Pneumonia due to Pseudomonas aeruginosa:part II:antimicrobial resis-tance, pharmacodynamic concepts, and antibiotic therapy[J]. Chest, 2011, 139(5):1172-1185.
[7] GELLATLY S L, HANCOCK R E W. Pseudomonas aeruginosa:new insights into pathogenesis and host defenses[J]. Pathog Dis, 2013, 67(3):159-173.
[8]袁婧婧,关伟杰,李惠敏,等.吸入性抗生素治疗成人支气管扩张症的有效性与安全性[J].中华结核和呼吸杂志,2017, 40(1):61-63.
[9]李虎.雾化吸入阿米卡星药代动力学及对G-杆菌所致呼吸机相关性肺炎的治疗作用[D].复旦大学, 2012.
[10] XU L, ZHANG F, DU S, et al. Inhaled antibiotics in noncystic fibrosis bronchiectasis:A meta-analysis[J]. Pharmazie, 2016, 71(9):491-498.